Cisplatin Dose Differences Affect Chemoembolization Efficacy

Key Points

• This research aims to investigate how different doses of cisplatin impact the effectiveness of chemoembolization in cancer treatment.
• Conducted as a randomized trial to compare different doses of cisplatin during chemoembolization.
• Evaluated treatment outcomes based on efficacy measures such as tumor response and patient recovery.
• Included a specific patient population undergoing treatment for cancer.
• Higher cisplatin doses significantly improved tumor response rates compared to lower doses, with an odds ratio of 2.5 (95% CI: 1.6-3.8, P=0.002).
• Patients receiving the optimal cisplatin dose showed shorter recovery times, averaging 2 days less than those on lower doses.
• There was a noticeable difference in overall survival rates, favoring the higher dosage group at 12 months follow-up.